Aduhelm Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to aging global population, lack of curative alzheimer treatments, advances in amyloid research, rising dementia prevalence, increased neurological clinical trials.

The growth in the forecast period can be attributed to growth in alzheimer patient pool, demand for early intervention therapies, expansion of biomarker based diagnosis, increased healthcare spending on neurology, development of next generation monoclonal antibodies. Major trends in the forecast period include growing focus on disease modifying alzheimer therapies, rising use of monoclonal antibodies in neurology, increased investment in neurodegenerative research, emphasis on early alzheimer diagnosis, expansion of amyloid targeting treatments.

The growing prevalence of Alzheimer’s disease is expected to drive the expansion of the Aduhelm market in the coming years. Alzheimer’s disease is a progressive neurodegenerative condition marked by a gradual decline in cognitive abilities, including memory, reasoning, and behavior. Its increasing prevalence is influenced by a combination of demographic trends, medical factors, and broader societal changes, particularly the aging population. Aduhelm (aducanumab-avwa) is used in the treatment of Alzheimer’s disease by targeting and reducing amyloid-beta plaques in the brain, which are thought to play a key role in disease progression. For example, in May 2024, according to the Alzheimer Society, a UK-based organization supporting people affected by dementia, an estimated 982,000 individuals in the UK were living with dementia, a number projected to rise to 1.4 million by 2040. As a result, the increasing prevalence of Alzheimer’s disease is contributing to the growth of the Aduhelm market.

Companies operating in the Aduhelm market are increasingly focusing on the development of innovative solutions, such as self-injectable monoclonal antibody formulations, to improve patient convenience and treatment adherence. Self-injectable formulations allow patients to administer maintenance doses independently using prefilled pens or syringes, reducing reliance on hospital-based infusions. For instance, in 2025, Eisai and Biogen, a biopharmaceutical collaboration between Japan- and US-based companies specializing in neurological and antibody-based therapies, introduced Leqembi Iqik, a self-injectable lecanemab pen. This product features a user-friendly prefilled pen designed for at-home administration, a maintenance-focused dosing regimen, safety and tolerability comparable to the intravenous formulation, and a design intended to reduce needle-related anxiety.

In December 2024, AbbVie, a US-based biopharmaceutical company, acquired Aliada Therapeutics for $1.4 billion. Through this acquisition, AbbVie aims to strengthen its Alzheimer’s disease pipeline by gaining access to Aliada’s blood-brain barrier delivery technology and its lead candidate, ALIA-1758. Aliada Therapeutics is a US-based biotechnology company focused on developing central nervous system therapies using its proprietary MODEL platform to enhance drug delivery to the brain.

Major companies operating in the aduhelm market are Biogen Inc., Eisai Co. Ltd.

North America was the largest region in the aduhelm market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aduhelm market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the aduhelm market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the aduhelm market by raising costs for imported biologic ingredients, infusion related equipment, and specialized manufacturing inputs. These impacts are more pronounced in regions relying heavily on imported monoclonal antibodies, including parts of europe and asia pacific. Higher treatment costs have influenced reimbursement discussions and hospital adoption rates. However, tariffs have encouraged pharmaceutical companies to expand local biologics manufacturing capacity. This supports long-term supply continuity and reduces future exposure to global trade fluctuations.

The aduhelm market research report is one of a series of new reports that provides aduhelm market statistics, including aduhelm industry global market size, regional shares, competitors with a aduhelm market share, detailed aduhelm market segments, market trends and opportunities, and any further data you may need to thrive in the aduhelm industry. This aduhelm market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Aduhelm (aducanumab) is a prescription medication developed by Biogen and Eisai Co., Ltd. It is a monoclonal antibody created to treat Alzheimer’s disease by targeting and reducing amyloid-beta plaques in the brain, which are thought to play a role in disease progression.

The primary indications for Aduhelm include mild cognitive impairment and mild dementia. Mild cognitive impairment (MCI) is defined as a noticeable decline in cognitive functions such as memory, attention, and reasoning that is greater than what is typically expected with aging but does not significantly disrupt daily activities. Aduhelm is distributed through hospitals and clinics as well as retail and specialty pharmacies and is used by various end users, including adult and geriatric patients.

The aduhelm market consists of sales of products including aducanumab-avwa, Aduhelm injection, donanemab, and Aricept. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.